Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 568
- Registration Number
- NCT04592419
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸Vitreo Retinal Consultants and Surgeons, Wichita, Kansas, United States
🇺🇸Tennessee Retina PC, Nashville, Tennessee, United States
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
- Target Recruit Count
- 576
- Registration Number
- NCT04480463
- Locations
- 🇪🇸
SCD Research Site, Zaragoza, Spain
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
- Conditions
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT04469595
- Locations
- 🇺🇸
Investigative Site, Warrenton, Virginia, United States
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
- Conditions
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 660
- Registration Number
- NCT04429503
- Locations
- 🇭🇺
Regeneron Study Site 1, Pecs, Baranya, Hungary
🇬🇧Regeneron Study Site, London, United Kingdom
🇺🇸Regeneron Study Site 2, San Antonio, Texas, United States
Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 23
- Registration Number
- NCT04411693
- Locations
- 🇺🇸
Retina Consultants of Houston, Houston, Texas, United States
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
- Conditions
- Interventions
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04370379
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
- Conditions
- Interventions
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT04331730
- Locations
- 🇩🇪
nordBLICK Augenklinik Bellevue, Kiel, Germany
🇺🇸Sierra Eye Associates, Reno, Nevada, United States
🇩🇪Internationale Innovative Ophthalmochirurgie GbR, Düsseldorf, Germany
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 576
- Registration Number
- NCT04270747
- Locations
- 🇨🇦
Clinique d'ophtalmologie des laurentides, Boisbriand, Quebec, Canada
🇵🇱Szpital Sw. Wojciecha, Poznan, Wielkopolskie, Poland
🇸🇰Univerzitna nemocnica Bratislava, Bratislava, Bratislavský Kraj, Slovakia
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Ribomic USA Inc
- Target Recruit Count
- 94
- Registration Number
- NCT04200248
- Locations
- 🇺🇸
Bay Area Retina Associates, Walnut Creek, California, United States
🇺🇸Valley Retina Institute, PA, McAllen, Texas, United States
🇺🇸Advanced Research, LLC, Coral Springs, Florida, United States
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 106
- Registration Number
- NCT04126317
- Locations
- 🇵🇷
Regeneron Study Site, Arecibo, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.